INVESTMENT SECURITIES (Tables)

6 Months Ended

Mar. 31, 2022

Disclosure Investment Securities Abstract

Schedule of investment securities

18,300 Common Shares of Oncology Pharma, Inc.
	Basis		Fair Value		Total Unrealized Losses		Net Unrealized Gain or (Loss) realized during the quarter    ended December 31,2021
$	677,100	$	67,710	$	602,985	$	(123,891	)